Galectin Therapeutics Inc. (GALT): Price and Financial Metrics

Galectin Therapeutics Inc. (GALT): $2.73

0.11 (+4.20%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add GALT to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#178 of 356

in industry

GALT Price/Volume Stats

Current price $2.73 52-week high $4.27
Prev. close $2.62 52-week low $1.28
Day low $2.58 Volume 114,200
Day high $2.76 Avg. volume 135,395
50-day MA $3.21 Dividend yield N/A
200-day MA $2.23 Market Cap 169.66M

GALT Stock Price Chart Interactive Chart >


Galectin Therapeutics Inc. (GALT) Company Bio


Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company was founded in 2000 and is based in Norcross, Georgia.


GALT Latest News Stream


Event/Time News Detail
Loading, please wait...

GALT Latest Social Stream


Loading social stream, please wait...

View Full GALT Social Stream

Latest GALT News From Around the Web

Below are the latest news stories about GALECTIN THERAPEUTICS INC that investors may wish to consider to help them evaluate GALT as an investment opportunity.

Galectin Therapeutics Inc (GALT) Reports Increased Net Loss in Q3 2023

Company Faces Higher R&D Expenses Amid Progress in Clinical Programs

Yahoo | November 13, 2023

UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

NORCROSS, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended September 30, 2023. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov. Joel Lewis, Chief Executive Officer and President

Yahoo | November 13, 2023

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

NORCROSS, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended September 30, 2023. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov. Joel Lewis, Chief Executive Officer and President

Yahoo | November 13, 2023

Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLD

Pharmacokinetics and safety of belapectin in patients with hepatic insufficiencyLack of impact of belapectin on cardiac repolarization (QT interval)Very High Elevation of Gamma-Glutamyl Transpeptidase (GGT) as a new marker of disease progression in patient with portal hypertension and liver cirrhosisClinical significance and interpretation of serum galectin-3 levels in patients with advanced liver diseaseImpact of obesity and muscle wasting to evaluate renal function in patients with portal hype

Yahoo | November 3, 2023

Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023

NORCROSS, Ga., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright 7th Annual NASH Investor Conference being held virtually on October 24, 2023. Dr. Pol F. Boudes, Galectin Therapeutics’ Chief Medical Officer, will deliver a corporate presentation on Tuesday, October 24, 2023 at 11:30 AM ET. A live webcast of the discussion will be

Yahoo | October 23, 2023

Read More 'GALT' Stories Here

GALT Price Returns

1-mo -3.87%
3-mo 32.52%
6-mo 70.63%
1-year 88.28%
3-year -25.61%
5-year -26.02%
YTD 64.46%
2023 46.90%
2022 -45.41%
2021 -7.59%
2020 -21.68%
2019 -16.62%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!